Specialists Ready to Advance Your Next Genitourinary Trial.
Genitourinary (GU) oncology is one of Novella’s largest areas of focus. More than 65% of our oncology trials have targeted solid tumor indications, including a number of rare cancers such as non-muscle invasive bladder cancer or renal cell carcinoma. We have supported 60 trials specifically in bladder, prostate and renal cancer indications, spanning a wide modality of drug classes including chemotherapies, targeted small molecules, and biologics, including antibody-drug conjugates. More than twenty of these studies are currently active, including full-service support for a number of large, global programs.
Learn more about our experience with active GU studies around the world.